A crisis has unfolded at SkinBioTherapeutics, an Aim-listed skin healthcare company, following the abrupt resignation of its chief executive, Stuart Ashman. The company revealed significant accounting discrepancies that have led
A crisis has unfolded at SkinBioTherapeutics, an Aim-listed skin healthcare company, following the abrupt resignation of its chief executive, Stuart Ashman. The company revealed significant accounting discrepancies that have led






